| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 5 Feb 2025 |
| LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December 2024 And Other Business if any. UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2024 (As Per BSE Announcement Dated on: 13/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 5 Nov 2024 |
| LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30 2024. UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2024 (As Per BSE Announcement Dated on 14.11.2024) | ||
| Board Meeting | 8 Aug 2024 | 30 Jul 2024 |
| LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30 2024 along with any other business if any. Out come of Un-Audited Financial Results for the Quarter Ended 30-June-2024 (As Per BSE Announcement Dated on 08.08.2024) | ||
| Board Meeting | 16 May 2024 | 8 May 2024 |
| LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2024. Outcome of Audited Financial Results for Quarter and year Ended on 31st March, 2024 (As Per BSE Announcement dated on 16.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
